A citation-based method for searching scientific literature

Mark S Fineman, Thomas A Bicsak, Larry Z Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain D Baron. Diabetes Care 2003
Times Cited: 264







List of co-cited articles
952 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
939
53

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
51

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
897
48

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
717
34

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
31

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Bernard Zinman, Byron J Hoogwerf, Santiago Durán García, Denái R Milton, Joseph M Giaconia, Dennis D Kim, Michael E Trautmann, Robert G Brodows. Ann Intern Med 2007
345
30

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C Klonoff, John B Buse, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, John H Holcombe, Matthew E Wintle, David G Maggs. Curr Med Res Opin 2008
547
29

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Orville G Kolterman, John B Buse, Mark S Fineman, Eling Gaines, Sonja Heintz, Thomas A Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang,[...]. J Clin Endocrinol Metab 2003
421
29

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman, Kristin Taylor. Diabetes Care 2007
336
27

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
600
27

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
783
24

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Orville G Kolterman, Dennis D Kim, Larry Shen, James A Ruggles, Loretta L Nielsen, Mark S Fineman, Alain D Baron. Am J Health Syst Pharm 2005
297
23


Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
618
22




Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
765
20



One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Mathijs C Bunck, Michaela Diamant, Anja Cornér, Bjorn Eliasson, Jaret L Malloy, Rimma M Shaginian, Wei Deng, David M Kendall, Marja-Riitta Taskinen, Ulf Smith,[...]. Diabetes Care 2009
303
18

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Michaela Diamant, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Kristin Taylor, Michael Trautmann. Lancet 2010
322
17


One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Kristine B Degn, Claus B Juhl, Jeppe Sturis, Grethe Jakobsen, Birgitte Brock, Visvanathan Chandramouli, Joergen Rungby, Bernard R Landau, Ole Schmitz. Diabetes 2004
330
16


Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
435
16



DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
299
15

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
L B Knudsen, P F Nielsen, P O Huusfeldt, N L Johansen, K Madsen, F Z Pedersen, H Thøgersen, M Wilken, H Agersø. J Med Chem 2000
445
14

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
Frauke Fehse, Michael Trautmann, Jens J Holst, Amy E Halseth, Nuwan Nanayakkara, Loretta L Nielsen, Mark S Fineman, Dennis D Kim, Michael A Nauck. J Clin Endocrinol Metab 2005
228
14




Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
Mark S Fineman, Larry Z Shen, Kristin Taylor, Dennis D Kim, Alain D Baron. Diabetes Metab Res Rev 2004
163
13

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
C M Edwards, S A Stanley, R Davis, A E Brynes, G S Frost, L J Seal, M A Ghatei, S R Bloom. Am J Physiol Endocrinol Metab 2001
350
13

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
13


Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Tina Vilsbøll, Milan Zdravkovic, Tu Le-Thi, Thure Krarup, Ole Schmitz, Jean-Pierre Courrèges, Robert Verhoeven, Ingrid Bugánová, Sten Madsbad. Diabetes Care 2007
339
13

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Helle Linnebjerg, Soomin Park, Prajakti A Kothare, Michael E Trautmann, Kenneth Mace, Mark Fineman, Ian Wilding, Michael Nauck, Michael Horowitz. Regul Pept 2008
169
13

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
L Blonde, E J Klein, J Han, B Zhang, S M Mac, T H Poon, K L Taylor, M E Trautmann, D D Kim, D M Kendall. Diabetes Obes Metab 2006
331
13



Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen, Kasper Almholt, Anne S de Boer, Daniel J Drucker, Carsten Gotfredsen, Frederikke Lihme Egerod, Anne Charlotte Hegelund, Helene Jacobsen,[...]. Endocrinology 2010
338
13

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
663
12

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Ralph A DeFronzo, Ted Okerson, Prabhakar Viswanathan, Xuesong Guan, John H Holcombe, Leigh MacConell. Curr Med Res Opin 2008
287
12

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
12


The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.